Core Viewpoint - The company has established a strategic partnership with Taiwan-based Dongshenghua Pharmaceutical Co., Ltd. to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan [1] Group 1: Partnership Details - The agreement grants Dongshenghua Pharmaceutical exclusive rights as a distributor in Taiwan for the registration, importation, promotion, distribution, marketing, and sale of BRIMOCHOL™ PF [1] Group 2: Regulatory Milestones - In June 2025, Tenpoint Therapeutics, Ltd., the developer of BRIMOCHOL™ PF, announced that the FDA has accepted the new drug application for the product [1] - The FDA has set a review deadline for BRIMOCHOL™ PF under the Prescription Drug User Fee Act (PDUFA) for January 28, 2026 [1]
兆科眼科-B(06622)拟与东生华制药于台湾地区共同推进BRIMOCHOLPF的临床导论及未来商业化